Achaogen is dedicated to addressing serious medical needs caused by the development of bacterial resistance to antibiotics. According to the CDC, over 70% of hospital bacterial infections are resistant to one or more classes of antibacterial drugs. In the United States alone, these infections cause more than 90,000 deaths per year and result in $4.5 billion in excess healthcare costs. Achaogen exists to apply its anticipatory science to the creation of novel medical therapies to combat tomorrow’s drug-resistant pathogens, specifically, the next generation of pan-resistant bacteria, including infections caused by Gram-negative pathogens and methicillin-resistant Staphylococcus aureus (MRSA). This scientific strategy represents a novel approach to addressing the global bacterial-resistance crisis.
South San Francisco, US
62 (est)+41%
Achaogen was founded in 2004 and is headquartered in South San Francisco, US

Achaogen Locations

South San Francisco, US

Achaogen Metrics

Achaogen Summary

Market capitalization

$357 M

Closing share price

Achaogen's current market capitalization is $357 M.

Achaogen Market Value History

We estimate that Achaogen's current employees are approximately 37% female and 63% male.

Achaogen Online Presence

Achaogen Company Life

You may also be interested in